From: Prognostic role of serum p53 antibodies in lung cancer
Ā | No. of cases | No. of patients with p53 overexpression |
---|---|---|
Age (years) | Ā | Ā |
ā¤60 | 27 | 16 (59.3%) |
>60 | 104 | 59 (56.7%) |
Total | 131 | 75 (57.3%) |
Sex | Ā | Ā |
Male | 101 | 57 (56.4%) |
Female | 30 | 18 (60.0%) |
Total | 131 | 75 (57.3%) |
Histological type | Ā | Ā |
NSCLC | Ā | Ā |
Adenocarcinoma | 59 | 26 (44.1%) |
Squamous cell carcinoma | 46 | 33 (71.7%) |
Bronchioloalveolar carcinoma | 5 | 1 (20.0%) |
Large cell carcinoma | 4 | 4 (100%) |
Anaplastic carcinoma | 4 | 4 (100%) |
Mixed carcinoma | 5 | 1 (20.0%) |
SCLC | 8 | 6 (75.0%) |
Total | 131 | 75 (57.3%) |
NSCLC stage | Ā | Ā |
I | 62 | 35 (56.4%) |
II | 17 | 9 (52.9%) |
III | 22 | 15 (68.2%) |
IV | 18 | 8 (44.4%) |
Missing | 4 | 2 (50.0%) |
Total | 123 | 69 (56.1%) |
NSCLC grade | Ā | Ā |
G1 | 3 | 1 (33.3%) |
G2 | 53 | 21 (39.6%) |
G3 | 60 | 40 (66.7%) |
Missing | 7 | 7 (100%) |
Total | 123 | 69 (56.1%) |